The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Merck will showcase results in innovative solutions in HIV treatment and prevention
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Subscribe To Our Newsletter & Stay Updated
